 Chromosomes, Human, Pair 1
"Chromosomes, Human, Pair 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification.
| Descriptor ID |
D002878
|
| MeSH Number(s) |
A11.284.187.520.300.235.240 G05.360.162.520.300.235.240
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Chromosomes, Human, Pair 1".
- Anatomy [A]
- Cells [A11]
- Cellular Structures [A11.284]
- Chromosomes [A11.284.187]
- Chromosomes, Mammalian [A11.284.187.520]
- Chromosomes, Human [A11.284.187.520.300]
- Chromosomes, Human, 1-3 [A11.284.187.520.300.235]
- Chromosomes, Human, Pair 1 [A11.284.187.520.300.235.240]
- Biological Sciences [G]
- Genetic Phenomena [G05]
- Genetic Structures [G05.360]
- Chromosomes [G05.360.162]
- Chromosomes, Mammalian [G05.360.162.520]
- Chromosomes, Human [G05.360.162.520.300]
- Chromosomes, Human, 1-3 [G05.360.162.520.300.235]
- Chromosomes, Human, Pair 1 [G05.360.162.520.300.235.240]
Below are MeSH descriptors whose meaning is more specific than "Chromosomes, Human, Pair 1".
This graph shows the total number of publications written about "Chromosomes, Human, Pair 1" by people in UAMS Profiles by year, and whether "Chromosomes, Human, Pair 1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2019 | 1 | 0 | 1 | | 2018 | 1 | 1 | 2 | | 2015 | 2 | 0 | 2 | | 2014 | 2 | 0 | 2 | | 2013 | 2 | 0 | 2 | | 2012 | 0 | 2 | 2 | | 2011 | 2 | 1 | 3 | | 2010 | 1 | 0 | 1 | | 2009 | 2 | 0 | 2 | | 2008 | 1 | 0 | 1 | | 2007 | 0 | 1 | 1 | | 2006 | 2 | 0 | 2 | | 2005 | 1 | 0 | 1 | | 2004 | 0 | 2 | 2 | | 2003 | 1 | 3 | 4 | | 2002 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 1998 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Chromosomes, Human, Pair 1" by people in Profiles over the past ten years.
-
Sawyer JR, Tian E, Walker BA, Wardell C, Lukacs JL, Sammartino G, Bailey C, Schinke CD, Thanendrarajan S, Davies FE, Morgan GJ, Barlogie B, Zangari M, van Rhee F. An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. Blood Cancer J. 2019 08 09; 9(8):62.
-
Veerapandiyan A, Oh D, Kornitzer J. Distal 1q21.1 and proximal 1q21.2 microduplication in a child with attention-deficit hyperactivity disorder. Acta Neurol Belg. 2019 Jun; 119(2):289-290.
-
Singh ZN, Richards S, El Chaer F, Duong VH, Gudipati MA, Waters EO, Koon S, Webley M, Pitel B, Hoppman NL, Baer MR, Zou YS. Cryptic ETV6-PDGFRB fusion in a highly complex rearrangement of chromosomes 1, 5, and 12 due to a chromothripsis-like event in a myelodysplastic syndrome/myeloproliferative neoplasm. Leuk Lymphoma. 2019 05; 60(5):1304-1307.
-
Weinhold N, Kirn D, Seckinger A, Hielscher T, Granzow M, Bertsch U, Egerer G, Salwender H, Blau IW, Weisel K, Hillengass J, Raab MS, Hose D, Goldschmidt H, Jauch A. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica. 2016 Mar; 101(3):e116-9.
-
Sawyer JR, Tian E, Heuck CJ, Johann DJ, Epstein J, Swanson CM, Lukacs JL, Binz RL, Johnson M, Sammartino G, Zangari M, Davies FE, van Rhee F, Morgan GJ, Barlogie B. Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. Blood. 2015 Jun 11; 125(24):3756-9.
-
Morgan GJ. Jumping translocations and high-risk myeloma. Blood. 2014 Apr 17; 123(16):2442-3.
-
Sawyer JR, Tian E, Heuck CJ, Epstein J, Johann DJ, Swanson CM, Lukacs JL, Johnson M, Binz R, Boast A, Sammartino G, Usmani S, Zangari M, Waheed S, van Rhee F, Barlogie B. Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood. 2014 Apr 17; 123(16):2504-12.
-
An G, Xu Y, Shi L, Shizhen Z, Deng S, Xie Z, Sui W, Zhan F, Qiu L. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica. 2014 Feb; 99(2):353-9.
-
Smetana J, Berankova K, Zaoralova R, Nemec P, Greslikova H, Kupska R, Mikulasova A, Frohlich J, Sevcikova S, Zahradova L, Krejci M, Sandecka V, Almasi M, Kaisarova P, Melicharova H, Adam Z, Penka M, Jarkovsky J, Jurczyszyn A, Hajek R, Kuglik P. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):123-30.
-
Elbabaa SK, Gokden M, Crawford JR, Kesari S, Saad AG. Radiation-associated meningiomas in children: clinical, pathological, and cytogenetic characteristics with a critical review of the literature. J Neurosurg Pediatr. 2012 Oct; 10(4):281-90.
-
Lai YY, Huang XJ, Cai Z, Cao XS, Chen FP, Chen XQ, Chen BA, Fang MY, Feng JF, Fu WL, Guo HY, Hou M, Hou J, Hu Y, Hu XT, Hu XM, Huang LQ, Jin J, Li JY, Li J, Li W, Liang YM, Liu T, Liu QF, Liu YH, Mao P, Ouyang J, Qiu LG, Qiu L, Shao CK, Shi B, Song YP, Sun ZM, Wang QS, Wang C, Wang JM, Wang YS, Wang Z, Wu JB, Wu YX, Xia RX, Xue YQ, Yang BZ, Yang G, Yang ZL, Yu L, Yuan Z, Zhang S, Zhang Y, Zhao HG, Zhao L, Zhou DB, Zou SH, Zhu YF. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China. Chin Med J (Engl). 2012 Aug; 125(15):2663-70.
-
Stephens OW, Zhang Q, Qu P, Zhou Y, Chavan S, Tian E, Williams DR, Epstein J, Barlogie B, Shaughnessy JD. An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. Blood. 2012 Jan 12; 119(2):503-12.
-
Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gregory WM, Jackson GH, Child JA, Davies FE, Morgan GJ. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res. 2011 Dec 15; 17(24):7776-84.
-
Shaughnessy JD, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E, Epstein J, Nair B, Stephens O, Williams R, Waheed S, Alsayed Y, Crowley J, Barlogie B. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood. 2011 Sep 29; 118(13):3512-24.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|